publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
fig
electron
micrograph
influenza
virion
singl
virion
surround
ha
spike
view
end
b
partial
disrupt
particl
show
matrix
layer
nprna
complex
c
section
viru
show
matrix
layer
lipid
bilay
courtesi
dr
hockley
chapter
earth
uniti
influenza
viru
manner
yet
found
probabl
parasit
hopesimpson
stuartharri
kilbourn
pereira
epidem
occur
inhabit
part
globe
regardless
latitud
longitud
altitud
climat
rainfal
temperatur
humid
race
sex
influenza
classic
pandem
viru
infect
man
although
pandem
viru
sinc
enteroviru
type
essenti
similar
epidemiolog
see
chapter
influenza
b
viru
also
caus
sharp
outbreak
result
signific
mortal
influenza
virion
rather
pleomorph
envelop
viru
often
take
doughnut
shape
visual
use
neg
stain
techniqu
fig
lipid
envelop
deriv
host
cell
viru
replic
stud
two
morpholog
distinguish
glycoprotein
spike
name
haemagglutinin
ha
neuraminidas
na
latter
take
morpholog
form
mushroom
narrow
extend
stalk
ha
triangular
cross
section
rather
like
tobleron
chocol
bar
spike
penetr
lipid
bilay
via
tail
hydrophob
amino
acid
contact
underli
layer
matrix
protein
protein
form
monomolecular
layer
probabl
contribut
major
way
structur
integr
virion
enclos
matrix
shell
nucleoprotein
pi
complex
close
assocci
ss
rna
viru
three
polymeras
protein
constitut
rna
transcriptas
enzym
kawakami
ishihama
review
mccauley
mahi
respons
initi
rna
replic
infect
cell
virion
rna
exist
separ
singl
strand
fragment
replic
independ
describ
shall
examin
detail
structur
function
structur
protein
rna
influenza
viru
tabl
known
composit
replic
influenza
probabl
human
viru
therefor
use
influenza
viru
model
safe
conclud
futur
scientif
investig
virus
follow
similar
pattern
haemagglutinin
ha
haemagglutinin
ha
influenza
viru
trimer
k
mw
may
solubil
viral
membran
bromelain
enzym
digest
remov
mw
ctermin
hydrophob
anchor
peptid
subunit
haemagglutinin
typic
integr
membran
protein
character
threedomain
structur
larg
hydrophil
carbohydratecontain
domain
extern
surfac
membran
small
uncharg
hydrophob
peptid
amino
acid
span
viru
membran
small
hydrophil
domain
amino
acid
intern
side
membran
review
webster
et
al
pales
kingsburi
typic
membran
glycoprotein
haemagglutinin
chain
initi
synthes
includ
ntermin
hydrophob
signal
peptid
subsequ
remov
part
process
protein
transport
across
anchor
membran
polypeptid
chain
trimer
glycosyl
seven
site
total
carbohydr
mw
weight
ha
protein
major
determin
virul
influenza
viru
bosch
et
also
contain
import
antigen
determin
stimul
product
neutral
antibodi
follow
infect
immun
ha
protein
import
biolog
function
attach
host
cell
receptor
insid
cell
mediat
fusion
event
result
releas
rna
cell
infect
therefor
ha
repres
import
target
protein
point
view
vaccin
also
chemotherapi
henc
probabl
well
studi
human
viru
protein
import
characterist
ha
mosaic
characterist
antigen
determin
antigen
drift
result
singl
amino
acid
substitut
abil
also
undergo
major
antigen
chang
antigen
shift
amino
acid
sequenc
analysi
ha
differ
subtyp
show
howev
certain
stretch
conserv
rais
possibl
could
use
specif
target
new
antivir
vaccin
discuss
detail
refer
work
oligopeptid
inhibitor
viru
replic
point
view
vaccin
earlier
studi
anim
show
crossprotect
kilbourn
werner
subtyp
influenza
viru
influenza
b
virus
thought
ha
mediat
therefor
shield
antigen
determin
could
exist
recogn
easili
certain
anim
human
emphas
possibl
obtain
immunogen
induc
crossreact
antibodi
wide
varieti
strain
present
antigen
drift
shift
pose
major
problem
vaccin
efficaci
detail
studi
carri
ha
influenza
virus
use
xray
crystallographi
wilson
et
al
togeth
earlier
sequenc
data
porter
et
al
geth
et
al
allow
construct
accur
dimension
model
ha
precis
local
cell
bind
site
antigen
determin
fig
fusion
sequenc
regard
bind
site
distribut
conserv
amino
acid
structur
reveal
highli
conserv
region
surfac
pocket
distal
end
molecul
seem
suit
bind
hostcel
oligosaccharid
tent
receptor
bind
pocket
includ
conserv
residu
tyr
glu
trp
leu
highli
conserv
sequenc
haemagglutinin
amino
terminu
substitut
first
first
amino
acid
observ
sequenc
associ
activ
viru
penetr
hostcel
intern
lysosom
membran
initi
infect
cleavag
ha
point
requir
infect
penetr
vitro
membran
fusion
homolog
sequenc
present
cleavageactiv
site
sendai
viru
fusion
protein
cleavag
requir
infect
membran
fusion
activ
ntermin
sequenc
strongli
nonpolar
first
charg
side
chain
occur
posit
glu
unexpectedli
rich
glycin
could
indic
flexibl
presenc
unusu
conform
regard
antigen
bind
site
four
b
c
identifi
fig
analyz
antigen
mutant
select
laboratori
immunolog
pressur
monoclon
antibodi
yewdel
et
al
site
unusu
protrud
loop
amino
acid
project
local
molecular
surfac
form
centr
obviou
antibodybind
site
haemagglutinin
antigen
distinct
viru
epidem
signific
mutat
region
site
b
compris
extern
residu
helix
adjac
residu
along
upper
edg
pocket
tent
implic
viru
receptor
bind
two
substitut
haemagglutinin
viru
asn
asp
thr
tyr
two
viru
gln
ser
asn
characi
fig
schemat
diagram
ha
trimer
viru
trimer
contain
stem
globular
domain
contain
variabl
antigen
determin
b
c
known
present
whether
influenza
b
h
molecul
ident
assum
similar
teriz
site
lack
sequenc
inform
region
haemagglutinin
sever
variant
leav
comparison
incomplet
site
c
bulg
tertiari
structur
disulphid
bond
cy
cy
distal
tip
molecul
compris
anoth
antibodybind
site
see
fig
haemagglutinin
virus
epidem
period
substitut
cluster
region
first
three
site
note
amino
acid
substitut
note
caus
antigen
variat
extern
site
depart
sever
amino
acid
substitut
haemagglutinin
natur
laboratoryselect
antigen
mutant
occur
interfac
region
subunit
haemagglutinin
trimer
amino
acid
may
recogn
result
rel
movement
globular
region
expos
interfac
region
howev
possibl
actual
antibodi
bind
site
remot
amino
acid
affect
exact
fit
interfac
might
disturb
substitut
list
complet
sequenc
rna
segment
code
group
specif
matrix
antigen
two
strain
h
l
n
report
well
partial
sequenc
number
strain
review
pales
kingsburi
follow
first
aug
codon
posit
strand
rna
protein
rather
hydrophob
rich
arginin
encod
comparison
sequenc
rna
segment
udorn
h
n
strain
show
sequenc
code
matrix
virus
isol
year
apart
highli
conserv
keep
antigen
studi
comparison
nucleotid
rna
segment
five
human
h
l
n
strain
isol
year
period
suggest
segment
retain
throughout
antigen
shift
ha
na
type
h
addit
complet
sequenc
contain
second
open
read
frame
overlap
protein
sequenc
nucleotid
three
mrna
transcrib
rna
segment
isol
one
mrna
consist
uninterrupt
nearli
fulllength
copi
rna
segment
respons
product
protein
protein
gener
splice
product
mrna
nucleotid
encod
ntermin
nine
amino
acid
nearli
nucleotid
splice
read
frame
chang
protein
product
correspond
identifi
infect
cell
addit
third
mrna
found
would
code
peptid
ident
c
terminu
product
yet
isol
nucleoprotein
np
nucleoprotein
one
groupspecif
antigen
influenza
virus
distinguish
influenza
b
c
virus
stuartharri
schild
probabl
constitut
backbon
helic
intern
complex
associ
rna
segment
three
differ
polymeras
protein
n
p
gene
viru
nucleotid
long
capabl
encod
protein
amino
acid
residu
mw
rich
arginin
doubl
immunodiffus
test
show
antigen
differ
np
h
strain
recent
studi
monoclon
antibodi
np
h
virus
shown
antigen
variat
occur
molecul
schild
et
al
n
p
molecul
possess
least
three
nonoverlap
antigen
area
one
area
strain
test
monoclon
antibodi
conserv
domain
inhibit
vitro
transcript
viral
rna
suggest
region
np
involv
rna
transcript
van
wyke
et
al
rna
segment
code
least
two
nonstructur
polypeptid
nsi
translat
separ
mrna
review
pales
kingsburi
lamb
et
al
ingli
et
al
map
sequenc
studi
shown
overlap
amino
acid
translat
differ
read
frame
polypeptid
nsl
share
amino
acid
n
termini
sequenc
mrna
delet
nucleotid
rejoin
rest
mrna
read
frame
function
nsl
establish
nsl
made
larg
amount
accumul
nucleu
whilst
made
late
infect
found
predominantli
cytoplasm
intern
protein
infect
cell
henc
less
avail
antibodi
would
expect
show
less
sequenc
variat
surfac
glycoprotein
ha
na
accordingli
comparison
sequenc
ns
gene
fowl
plagu
two
human
influenza
strain
show
differ
see
pales
kingsburi
open
read
frame
potenti
code
extra
polypeptid
note
noncod
virion
rna
ns
gene
fpv
present
ns
gene
protein
correspond
extra
gene
yet
identifi
three
largest
protein
virion
pl
molecular
weight
respect
found
associ
nucleoprotein
virion
rna
carri
polymeras
activ
transcrib
invad
viral
rna
protein
pi
probabl
requir
complementari
rna
synhesi
np
virion
rna
synthesi
complet
nucleotid
sequenc
two
three
polymeras
gene
strain
determin
extent
variat
polymeras
gene
unknown
although
may
play
import
part
host
rang
virul
almond
defect
interf
di
influenza
viru
particl
gener
high
multipl
passag
permiss
cell
particl
interest
facilit
establish
persist
infect
cell
cultur
could
therefor
concern
latenc
contain
new
small
rna
molecul
absent
infecti
viru
gener
predominantli
massiv
intern
delet
three
p
gene
although
three
sequenc
one
small
rna
mosaic
sever
segment
least
two
polymeras
gene
neuraminidas
na
na
second
glycoprotein
surfac
virion
sever
role
suggest
neuraminidas
enzym
catalys
cleavag
ccketosid
linkag
termin
sialic
acid
adjac
sugar
residu
reaction
permit
transport
viru
mucin
destroy
haemagglutinin
receptor
host
cell
thu
allow
elut
progeni
viru
particl
infect
cell
remov
sialic
acid
carbohydr
moieti
newli
synthes
haemagglutinin
neuraminidas
also
necessari
prevent
selfaggreg
viru
gener
role
neuraminidas
may
facilit
mobil
viru
site
infect
protein
exhibit
antigen
shift
major
chang
amino
acid
sequenc
antigen
drift
minor
chang
n
amino
acid
sequenc
two
serolog
distinct
subtyp
neuraminidas
known
human
influenza
virus
n
subtyp
associ
viru
isol
time
subtyp
appear
asian
influenza
n
major
chang
structur
neuraminidas
occur
sinc
although
haemagglutinin
subtyp
chang
hong
kong
pandem
neuraminidas
influenza
viru
integr
membran
glycoprotein
tetram
molecular
weight
k
reduc
k
solubil
viru
pronas
sequenc
neuraminidas
sever
strain
ni
b
subtyp
known
hydrophob
ntermin
region
serv
anchor
neuraininidas
membran
enzym
subunit
contain
amino
acid
carbohydr
attach
four
place
crystalliz
product
pronas
digest
begin
residu
call
neuraminidas
head
carri
full
antigen
enzymat
capabl
membraneassoci
neuraminidas
describ
detail
structur
na
resolut
na
structur
unusu
symmetr
oligom
ident
polypeptid
chain
boxshap
head
connect
viru
membran
long
slender
stalk
crystal
stalk
remov
pronas
digest
liber
squar
head
retain
full
enzymat
antigen
capabl
fold
polypeptid
chain
uniqu
monom
contain
six
psheet
sheet
contain
four
strand
topolog
w
view
head
monom
consist
six
fourstrand
sheet
array
like
petal
flower
twist
like
blade
pinwheel
review
wiley
although
threedimension
structur
stem
unknown
may
even
unusu
amino
acid
cytoplasm
side
membran
follow
uncharg
primarili
hydrophob
peptid
span
membran
anchor
protein
lipid
anchor
also
act
signal
peptid
membran
transloc
remov
signal
peptidas
slender
stem
residu
unusu
contain
per
cent
oligosaccharid
molecul
four
site
exhibit
absolut
amino
acid
sequenc
homolog
among
na
variou
viru
strainsalthough
remaind
molecul
show
highli
signific
per
cent
homolog
thu
viral
membran
glycoprotein
na
ha
exhibit
novel
structur
featur
na
pinwheel
slender
stalk
ha
looplik
topolog
begin
end
membran
fibrou
stem
centr
long
triplestrand
coiledcoil
ahelic
four
carbohydr
chain
crystallin
na
distribut
two
top
two
bottom
boxshap
head
one
oligosaccharid
found
subunitsubunit
interfac
na
ha
oligosaccharid
attach
later
surfac
glycoprotein
posit
glycoprotein
might
expect
contact
protein
embed
membran
catalyt
site
na
locat
differ
fourier
analysi
crystal
soak
sialic
acid
site
surround
conserv
charg
residu
contain
three
hydrophob
residu
tyr
trp
leu
examin
locat
amino
acid
substitut
seri
drift
field
strain
three
antigen
variant
select
growth
monoclon
antisera
colman
colleagu
abl
propos
locat
antigen
determin
na
antigen
site
compos
loop
connect
strand
form
nearli
continu
surfac
encircl
catalyt
site
top
na
although
residu
activ
site
conserv
strain
strain
proxim
variabl
loop
site
suggest
signific
part
variabl
loop
could
interfer
antibodi
contact
activ
site
caviti
review
wiley
littl
known
precis
term
molecular
detail
interact
human
virus
includ
influenza
cell
receptor
howev
advent
rapid
sequenc
viru
glycoprotein
involv
interact
knowledg
sequenc
involv
increas
rapidli
recogn
pitfal
studi
earli
interact
virus
cell
import
one
whether
interact
observ
lead
infect
whether
simpli
observ
noninfecti
interact
nevertheless
studi
urgent
requir
data
obtain
could
easili
appli
exampl
design
specif
inhibitor
chemoprophylaxi
also
help
understand
import
problem
antibodyviru
interact
neutral
viru
cell
fusion
viru
host
rang
sialic
acid
known
essenti
compon
cell
surfac
receptor
influenza
paramyxovirus
polyoma
encephalomyocard
viru
virus
nevertheless
appear
exhibit
strict
vari
specif
precis
sialyloligosaccharid
sequenc
serv
receptor
determin
probabl
best
character
viru
receptor
glycophorin
sialo
glycoprotein
bind
site
influenza
viru
erythrocyt
sialic
acid
contain
glycolipid
gangliosid
occur
natur
plasma
membran
cell
act
receptor
cholera
toxin
interferon
glycoprotein
hormon
well
certain
virus
cours
gangliosid
glycoprotein
may
involv
adsorpt
singl
viru
approach
cell
viru
firstli
would
interact
glycoprotein
intim
interact
plasma
membran
contain
gangliosid
refer
imposs
make
gener
statement
viru
receptor
excel
exampl
reason
name
mark
differ
viru
cell
receptor
interact
even
genet
close
relat
virus
describ
carrol
et
al
author
describ
differ
adsorpt
properti
virus
erythrocyt
attribut
differ
sialyloligosaccharid
receptor
specif
erythrocyt
treat
vibrio
cholera
neuraminidas
remov
sialic
acid
modifi
cmpneuac
three
purifi
sialyltransferas
contain
either
gal
gal
gal
nac
linkag
cell
surfac
glycoprotein
two
virus
total
differ
specif
bind
respect
gal
gal
linkag
implic
studi
receptor
site
function
properti
ha
may
chang
independ
overal
antigen
properti
two
antigen
site
b
influenza
ha
molecul
fig
near
receptor
site
therefor
possibl
variat
receptor
specif
might
aris
natur
select
pressur
place
host
specifi
sialyloligosaccharid
present
secret
cell
surfac
glycoprotein
inde
recent
describ
select
subpopul
influenza
b
virus
cultiv
viru
mdck
cell
embryon
hen
egg
schild
et
al
latter
host
system
extrem
select
clone
popul
virion
differ
antigen
composit
detect
monoclon
polyclon
antibodi
compar
parent
viru
cultiv
mdck
cell
novel
implic
nonimmun
select
mechan
involv
host
cell
receptor
site
may
oper
select
gener
antigen
variant
influenza
viru
thu
contribut
toward
antigen
drift
evolut
viru
influenza
viru
redistribut
cell
surfac
soon
infect
patterson
oxford
unpublish
data
contrast
adenoviru
inhibit
redistribut
parallel
block
viru
uptak
differ
may
reflect
number
membran
receptor
avail
two
virus
suffici
number
suitabl
receptor
within
close
proxim
bound
influenza
viru
particl
would
requir
activ
movement
extens
diffus
receptor
evid
receptor
mediat
uptak
envelop
virus
occur
special
site
plasma
membran
known
coat
pit
ultrastructur
site
recogn
thicken
cytoplasm
side
membran
due
protein
call
clathrin
receptor
bound
ligand
taken
coat
pit
coat
vesicl
tyrrel
patterson
et
al
transport
lysosom
intracellular
site
fig
clathrin
coat
dissoci
soon
pinc
recycl
back
plasma
membran
recent
membran
fusion
mechan
entri
uncoat
thought
mainli
restrict
paramyxoviru
group
see
chapter
evid
fusion
play
role
uncoat
mani
envelop
virus
clear
mani
virus
site
fusion
whether
fusion
patterson
plasma
membran
uptak
pinocytosi
cytoplasm
vacuol
follow
fusion
disput
sever
differ
viru
group
find
nterminu
highli
conserv
throughout
differ
influenza
serotyp
almost
ident
nterminu
sendai
viru
protein
strengthen
fusion
argument
thu
uptak
cytoplasm
vacuol
influenza
viru
still
face
problem
penetr
cellular
membran
releas
nucleic
acid
order
initi
infect
studi
sfv
heleniu
colleagu
observ
virion
enter
via
coat
pit
end
lysosom
parallel
studi
sfv
induc
fuse
plasma
membran
cell
adsorb
cell
viru
briefli
expos
prepar
warm
medium
ph
addit
low
ph
depend
fusion
viru
liposom
demonstr
data
propos
low
ph
environ
lysosom
promot
fusion
viral
lysosom
membran
result
releas
viral
nucleic
acid
cell
cytoplasm
claim
antivir
action
lysosomotrop
agent
chloroquin
amantadin
nh
mediat
abil
rais
lysosom
ph
ohkuma
pool
block
viru
infect
earli
stage
prior
transcript
shall
return
later
chapter
two
type
genom
transcript
synthesis
infect
viru
mrna
incomplet
transcript
polyadenyl
end
addit
non
viral
primer
sequenc
end
unpolyadenyl
complet
transcript
consid
templat
genom
replic
smith
hay
differ
mechan
respons
product
two
class
crna
surprisingli
littl
known
interrelationship
synthesi
vrna
exampl
recent
data
howev
indic
vrna
synthesi
regul
throughout
infect
may
involv
select
transcript
templat
regul
vrna
synthesi
may
larg
respons
control
product
viru
mrna
smith
hay
cell
nucleu
play
import
role
viru
replic
influenza
unabl
replic
enucl
cell
replic
nucleat
cell
prevent
actinomycin
mitomycin
c
treatment
earli
infect
see
fig
extra
detail
certain
respect
initi
influenza
viru
rna
transcript
resembl
initi
protein
synthesi
cellular
messeng
rna
eukaryot
system
affin
label
affin
chromatographi
experi
demonstr
polypeptid
mw
k
compon
eukaryot
initi
factor
involv
cap
bind
host
cell
recent
shown
fig
scheme
replic
influenza
viru
genom
mccauley
mahi
transcript
input
genom
rna
transcript
crna
newli
synthes
vrna
necessari
interact
step
primari
transcript
occur
absenc
protein
synthesi
requir
host
cell
transcript
step
crna
synthesi
input
genom
vrna
step
select
amplifi
vrna
synthesi
direct
crna
requir
ongo
protein
synthesi
step
transcript
newli
synthes
vrna
form
mrna
requir
host
cell
cap
step
modif
mrna
splice
requir
protein
synthesi
undefin
host
cell
function
presenc
atp
mg
ion
oxid
reoviru
mrna
crosslink
two
protein
mw
k
k
may
structur
relat
k
polypeptid
sonenberg
studi
monoclon
antibodi
indic
k
capbind
polypeptid
may
contain
even
larger
protein
precursor
also
demonstr
translat
cap
mrna
competit
inhibit
variou
cap
analogu
et
al
roman
et
al
influenza
viru
uniqu
featur
use
host
cellcod
cap
rna
primer
synthesi
mrna
fig
prime
reaction
cap
togeth
nucleotid
cleav
host
rna
viral
endonucleas
subsequ
use
initi
viral
rna
transcript
krug
et
al
result
host
rnaderiv
cap
sequenc
found
link
viral
mrna
cap
transfer
reaction
also
perform
vitro
use
varieti
mrna
globin
mrna
reoviru
mrna
primer
activ
primer
investig
rna
contain
cap
effici
initi
viral
mrna
synthesi
addit
natur
nirna
synthet
polynucleotid
cap
poli
cap
poli
au
prime
viral
transcript
thu
bind
cap
rna
viral
transcript
complex
clearli
caus
interact
base
pair
viral
templat
rna
leav
cap
structur
common
signal
recognit
primer
rna
therefor
seem
like
cap
recognit
site
must
present
within
polymeras
complex
recent
cap
bind
protein
establish
virion
polymeras
protein
blaa
et
al
detail
krug
et
al
identifi
base
repres
primer
pglobin
mrna
transfer
viral
rna
transcript
use
izsilabel
globin
mrna
primer
vitro
transcript
found
predomin
sequenc
end
viral
mrna
segment
ident
first
nucleotid
plu
cap
terminu
mrna
sequenc
acuugcuuuu
c
residu
label
result
indic
possibl
first
base
mrna
transfer
viral
mrna
fig
analysi
minor
oligonucleotid
found
viral
mrna
indic
shorter
fragment
mrna
base
length
sometim
transfer
transfer
piec
like
link
g
first
base
incorpor
transcriptas
prime
mechan
involv
recognit
methyl
cap
structur
rna
contain
cap
activ
primer
remov
cap
chemic
enzymat
treatment
elimin
prime
activ
activ
restor
enzymat
recap
rna
absenc
either
methyl
group
cap
rna
greatli
addit
refer
see
mcgeoch
et
al
skehel
lamb
et
al
webster
et
al
duce
prime
activ
absenc
methyl
group
complet
elimin
activ
similar
prime
cap
rna
also
appar
occur
uninfect
cell
aamanitinsensit
rna
polymeras
step
requir
viral
rna
transcript
vivo
allud
explain
ie
host
rna
polymeras
requir
synthesi
cap
rna
primer
cap
cellular
rna
made
infect
preexist
infect
serv
primer
one
possibl
newli
synthes
cap
cellular
rna
serv
primer
preexist
newli
synthes
cap
rna
tie
ribonucleoprotein
structur
includ
polyribosom
use
viral
transcriptas
viral
transcriptas
would
expect
function
near
site
synthesi
cap
cellular
rna
nucleu
sever
line
evid
suggest
step
viral
rna
transcript
occur
nucleu
yet
directli
demonstr
sequenc
event
repres
target
develop
new
inhibitor
influenza
viru
much
less
known
later
event
influenza
viru
replic
virion
protein
synthes
transport
site
viru
bud
glycoprotein
na
ha
insert
plasma
membran
detail
whilst
presum
transmembran
cross
end
glycoprotein
matrix
protein
align
intern
side
plasma
membran
assum
specif
site
interact
n
p
contain
rna
p
protein
complex
result
spontan
format
complet
particl
bud
cell
surfac
fig
obvious
mani
question
remain
answer
includ
mechan
assur
correct
amount
rna
per
virion
trigger
process
bud
detail
bud
consid
enzymat
activ
na
ensur
releas
virion
sinc
inhibit
na
activ
result
aggreg
viru
cell
surfac
absenc
self
aggreg
via
naha
bond
influenza
virus
classifi
three
type
b
con
basi
typespecif
nucleoprotein
matrix
protein
antigen
although
three
virus
also
show
differ
biolog
epidemiolog
properti
major
pandem
far
record
caus
influenza
viru
also
type
associ
influenza
avian
equin
swine
speci
easterday
laver
type
b
influenza
caus
restrict
epidem
isol
human
wherea
type
c
caus
even
fewer
clinic
problem
human
also
isol
pig
guo
et
al
type
influenza
virus
classifi
subtyp
base
antigen
characterist
surfac
antigen
haemagglutinin
ha
neuraminidas
na
twelv
distinct
ha
subtyp
nine
na
subtyp
recogn
nomenclatur
system
influenza
virus
recommend
world
health
organ
thirteenth
ha
subtyp
recent
identifi
tabl
implicit
system
virus
common
h
n
subtyp
ha
na
antigen
shown
relat
convent
laboratori
test
relationship
occur
subtyp
howev
includ
among
virus
common
subtyp
design
strain
show
consider
degre
antigen
variat
antigen
drift
thu
human
viru
contain
ha
n
antigen
demonstr
relat
ahong
viru
show
consider
degre
differ
within
strain
singl
subtyp
differ
deduc
amino
acid
sequenc
gener
less
recent
extens
data
reveal
differ
ntermin
region
two
strain
h
virus
close
almost
equal
differ
amino
acid
sequenc
two
closest
subtyp
thu
chang
must
involv
drastic
mechan
sever
possibl
could
mention
explain
antigen
shift
new
viru
may
caus
epidem
man
mani
year
previous
remain
hidden
ever
sinc
evid
kind
event
obtain
thu
strain
russian
flu
h
n
reappear
anshan
northern
china
may
subsequ
spread
rest
world
seem
ident
gene
viru
caus
influenza
epidem
hidden
place
could
includ
anim
reservoir
refriger
even
persist
latent
infect
human
new
virus
may
deriv
anim
avian
virus
one
strain
human
influenza
shown
recombin
reassort
hong
kong
viru
contain
na
gene
asian
strain
human
influenza
ha
antigen
relat
virus
amino
acid
sequenc
homolog
virus
subtyp
donat
viru
could
one
contain
hong
kong
ha
persist
much
earlier
human
influenza
epidem
maintain
unchang
way
russian
flu
anim
bird
viru
could
becom
infecti
man
easterday
laver
unpr
dictabl
one
major
worri
featur
influenza
togeth
cours
demonstr
virul
human
explain
much
work
carri
viru
mortal
data
million
peopl
live
member
state
approxim
one
quarter
world
popul
show
two
million
death
acut
respiratori
diseas
occur
annual
review
lennett
major
acut
respiratori
diseas
attribut
virus
famili
influenza
b
virus
caus
signific
number
death
highest
mortal
influenza
epidem
alway
note
among
certain
group
identifi
special
risk
group
shall
see
signific
group
person
later
discuss
prevent
influenza
vaccin
chemoprophylaxi
special
risk
person
constitut
main
target
group
mass
vaccin
chemoprophylaxi
influenza
gener
practic
absenc
broad
spectrum
antivir
less
efficaci
current
vaccin
person
special
risk
group
old
peopl
gener
year
age
see
tabl
babi
month
age
person
diabet
chronic
heart
kidney
respiratori
ailment
earli
william
farr
estim
impact
influenza
london
estim
excess
mortal
viz
subtract
number
death
influenzafre
winter
number
death
epidem
winter
stepwis
multipl
regress
model
use
tillett
et
al
obtain
estim
use
uk
data
offic
popul
census
survey
gener
figur
year
period
analyz
factor
known
influenc
weekli
return
includ
season
variat
time
trend
morbid
mortal
result
analysi
shown
tabl
influenza
outbreak
caus
two
influenza
variant
also
influenza
b
virus
excess
death
record
due
respiratori
caus
repres
death
approxim
elderli
popul
uk
winter
excess
sick
benefit
claim
equival
ill
approxim
person
insur
viz
age
group
total
morbid
adult
popul
million
analysi
includ
children
wide
recogn
therefor
influenza
b
virus
form
worth
target
new
drug
vaccin
although
influenza
viru
one
studi
virus
particularli
point
view
molecular
biolog
viru
replic
morpholog
antigen
structur
mani
import
question
concern
biochem
basi
vimlenc
even
epidemiolog
viru
remain
unansw
specif
prevent
measur
often
undertaken
haphazardli
great
enthusiasm
mani
countri
characterist
ill
begin
suddenli
incub
period
day
shiver
malais
headach
ach
limb
muscl
pain
back
christi
temperatur
rise
rapidli
afflict
person
take
bed
main
feel
one
gener
malais
pain
discomfort
temperatur
rang
c
commonli
cheek
may
flush
eye
infect
throat
congest
fortun
ill
often
short
live
temperatur
drop
day
patient
bed
day
work
day
howev
older
patient
recoveri
period
quit
prolong
weak
lassitud
mark
gener
mortal
figur
suggest
death
case
young
children
tend
milder
diseas
older
children
adult
review
stuartharri
aspect
diagnosi
influenza
also
consid
fig
chest
complic
tend
occur
patient
previous
suffer
chronic
bronchiti
rheumat
ischaem
hypertens
heart
diseas
pneumonia
may
result
infect
viru
invas
staphylococci
viru
damag
epitheli
cell
invas
pneumococci
viral
pneumonia
present
overwhelm
infect
profound
toxaemiaso
much
respiratori
sign
may
notic
staphylococcu
pneumonia
clinic
sign
may
notic
respiratori
person
may
partial
recov
influenza
recoveri
interrupt
sudden
onset
dyspnoea
cyanosi
may
featur
sign
shock
collaps
blood
pressur
pneumococc
pneumonia
may
often
less
sever
onset
may
delay
patient
appear
post
influenza
convalesc
stage
classic
sign
lobar
consolid
note
respons
antibiot
usual
rapid
rare
complic
frequent
fatal
influenza
b
influenza
infect
rey
syndrom
fatti
degener
viscera
especi
liver
main
individu
aspect
pathogen
viz
virul
viru
mucou
surfac
interact
entri
host
tissu
viru
replic
avoid
host
defenc
spread
damag
host
tissu
organ
specif
review
sweet
smith
overal
virul
viru
may
depend
complex
interact
vari
factor
case
singl
factor
predomin
mim
bosch
et
al
burnet
scholtissek
et
al
rott
et
al
assess
degre
virul
pandem
moreov
antigen
variabl
viru
influenza
probabl
imposs
difficult
establish
record
differ
mortal
exampl
influenza
pandem
pandem
estim
time
higher
mortal
caus
increas
virul
viru
caus
former
pandem
whether
immun
statu
popul
differ
whether
addit
factor
popul
movement
unusu
foci
high
popul
densiti
world
war
contribut
nevertheless
quit
clear
variat
virul
influenza
virus
occur
laboratori
follow
infect
human
influenza
viru
invad
epitheli
surfac
respiratori
tract
mani
differ
type
cell
infect
includ
ciliat
intermedi
basal
goblet
cell
nasal
epithelium
rare
case
pneumonia
cell
line
alveoli
review
sweet
smith
human
may
infect
initi
settl
larg
particl
contain
viru
upper
respiratori
tract
fine
particl
lower
respiratori
tract
particularli
interest
commonli
influenza
infect
upper
respiratori
tract
human
specul
lung
alveolar
macrophag
may
particularli
effici
remov
destroy
virion
presenc
nonspecif
inhibitor
mucoprotein
neutral
influenza
viru
infect
prevent
attach
viru
new
suscept
cell
influenza
viru
carri
henc
spread
downward
respiratori
tract
mucociliari
action
downward
drainag
rare
human
infect
lung
tissu
caus
death
primari
viru
pneumonia
tabl
summar
although
exhaust
attempt
last
decad
obtain
effect
inhibitor
influenza
b
viru
two
compound
apart
interferon
confirm
antivir
activ
man
name
amantadin
ribavirin
therefor
particular
attent
devot
two
molecul
amantadin
use
excel
illustr
problem
frustrat
develop
antiinfluenza
viru
compound
tabl
would
like
emphas
two
import
point
stage
firstli
influenza
viru
tnay
repres
rather
uniqu
viru
chemotherapi
arid
vaccin
may
use
complet
strategi
viru
control
field
secondli
realiz
past
search
new
influenza
inhibitor
oxford
carri
use
biolog
screen
procedur
less
random
test
synthes
molecul
swallow
cours
retrospect
possibl
deduc
whether
rather
depress
lack
success
due
particular
featur
viru
altern
random
search
galasso
et
al
question
may
answer
next
year
group
util
appear
design
approach
search
inhibitor
rna
transcriptas
fusion
neuraminidas
mrna
cap
etc
sequenc
studi
ha
na
viru
protein
provid
vast
amount
hard
biochem
data
new
logic
screen
procedur
base
excel
exampl
new
approach
synthesi
short
peptid
whose
sequenc
deduc
known
fusion
sequenc
n
terminu
richardson
et
al
cyclic
primari
amin
amantadin
symmetrel
first
remain
present
inhibitor
influenza
viru
replic
licens
sever
note
amantadin
also
use
treatment
parkinson
diseas
timberlak
vanc
schwab
et
al
countri
use
antivir
clinic
gener
commun
review
galbraith
hoffman
smorodintsev
et
tabl
arid
nevertheless
neither
origin
compound
molecular
deriv
tabl
rimantadin
zlydnikov
et
al
indulen
kalninya
gain
univers
accept
among
clinician
fulli
effect
compound
use
prophylact
therapeut
influenza
viru
infect
littl
doubt
rel
poor
usag
amantadin
reduc
interest
search
develop
new
antivir
influenza
respiratori
virus
import
establish
problem
face
amantadin
uniqu
compound
would
similar
hope
even
effect
antivir
respiratori
virus
could
ad
comparison
dearth
antivir
respiratori
virus
compound
act
herp
viru
infect
develop
acyclovir
pfa
may
soon
establish
first
antivir
use
larg
scale
commun
see
chapter
laboratori
studi
inhibit
influenza
virus
amin
includ
amantadin
ammonium
compound
establish
quit
earli
spectrum
antivir
activ
certain
compound
somewhat
restrict
fig
thu
although
certain
simpl
primari
amin
methylamin
inhibit
influenza
b
viru
vitro
eaton
et
al
oxford
schild
amantadin
littl
effect
influenza
b
virus
inhibit
influenza
virus
tabl
addit
studi
indic
differ
even
influenza
virus
differ
subtyp
regard
degre
inhibit
amantadin
certain
virus
hinl
poorli
inhibit
compound
wherea
virus
subtyp
exampl
well
inhibit
grunert
et
al
schild
sutton
retrospect
increas
resist
might
caus
multipl
mutat
undoubtedli
accumul
viru
extens
laboratori
passag
earli
laboratori
data
show
appar
heterogen
respons
influenza
virus
inhibit
amantadin
gave
rise
concern
new
epidem
subtyp
influenza
might
inhibit
amantadin
result
compound
licens
initi
usa
prophylaxi
influenza
virus
subtyp
demonstr
sensit
com
fig
arnantadin
molecul
test
antivir
activ
see
tabl
pound
new
pandem
influenza
ahong
viru
appear
opportun
lost
use
test
compound
larg
scale
first
wave
epidem
time
influenza
vaccin
avail
howev
compound
licens
usa
uk
prophylaxi
therapi
human
influenza
viru
summari
therefor
would
appear
see
recent
unpassag
influenza
virus
differ
human
subtyp
hlni
well
inhibit
amantadin
vitro
laboratori
anim
model
system
furthermor
earlier
viru
isol
good
correl
establish
studi
vitro
inhibitori
effect
amantadin
clinic
efficaci
therefor
anticip
recent
h
l
n
l
virus
would
inhibit
clinic
practic
recent
clinic
trial
confirm
optim
see
earlier
studi
oxford
et
al
show
amantadineresist
influenza
virus
could
select
passag
viru
mice
treat
high
mgkgday
dose
compound
passag
vitro
influenza
viru
inhibit
pgml
amantadin
wherea
singl
passag
presenc
drug
pgml
amantadin
requir
inhibit
replic
viru
isol
six
passag
vivo
influenza
strain
complet
resist
amantadin
relat
drug
rimantadin
number
laboratori
sinc
investig
genet
basi
amantadin
resist
produc
viru
recombin
amantadin
resist
vero
cell
cultur
infect
eidsocel
viru
incub
presenc
absenc
amantadin
overnight
cell
puls
methionin
min
cell
lysat
analys
electrophoresi
polyacrylamid
gel
follow
autoradiographi
quantiti
viru
induc
polypeptid
estim
densitomet
analysi
autoradiograph
analysi
trace
use
kontron
mop
digiplan
apparatu
note
polypeptid
synthesi
influenza
virus
well
inhibit
amantadin
antivir
effect
detect
repres
influenza
b
viru
amantadin
suscept
influenza
virus
faulkner
lubeck
et
al
way
transfer
drug
resist
correl
transfer
particular
gene
group
gene
present
result
differ
laboratori
somewhat
conflict
although
sever
group
agre
gene
code
matrix
protein
appear
cosegreg
amantadin
resist
interpret
howev
complic
extent
observ
use
differ
vitro
techniqu
influenza
viru
may
appear
inhibit
resist
drug
addit
data
determin
influenza
virul
suggest
multigen
linkag
biolog
properti
quit
possibl
howev
sever
gene
product
involv
mode
action
amantadin
product
gene
may
helper
activ
present
littl
extens
field
work
carri
search
rimantadin
amantadin
resist
virus
contact
person
treat
influenza
import
aspect
investig
sinc
quit
like
amantadin
resist
could
spread
among
field
virus
genet
reassort
influenza
h
l
n
l
virus
circul
present
commun
known
recombin
see
chapter
contain
gene
viru
subtyp
thu
intraor
intertyp
recombin
probabl
occur
rel
high
frequenc
ghendon
et
al
heider
et
al
recent
report
two
rel
resist
influenza
viru
isol
berlin
rimantadin
use
prophylat
howev
even
amantadin
sensit
virus
work
show
rather
poor
dose
respons
amantadin
therefor
studi
need
extend
confirm
studi
uk
would
suggest
occasion
field
isol
h
l
n
l
virus
partial
resist
amantadin
earli
biolog
studi
demonstr
amantadin
act
earli
stage
influenza
viru
infect
later
detail
studi
establish
point
action
approxim
late
stage
viru
uncoat
review
oxford
galbraith
recent
recognit
n
terminu
polypeptid
influenza
haemagglutinin
amino
acid
sequenc
similar
fusion
sequenc
f
protein
sendai
virus
also
demonstr
fusion
haemolysi
event
influenza
virus
cell
low
ph
white
et
al
led
hypothesi
import
role
fusion
infect
cell
influenza
viru
possibl
reinterpret
data
mode
action
amantadin
present
would
influenza
virus
penetr
suscept
cell
viropexi
thu
enter
cell
cyptoplasm
coat
vesicl
fig
compar
prelysosom
cytoplasm
vacuol
shown
low
ph
condit
influenza
hamedi
fusion
could
occur
sinc
configur
chang
ha
could
result
n
terminu
normal
distanc
either
end
molecul
contact
membran
vacuol
wilson
et
al
fusion
viral
vacuol
membran
would
occur
result
releas
viral
rna
subsequ
transport
cell
nucleu
initi
viral
rna
transcript
known
occur
amantadin
amin
known
increas
ph
intracytoplasm
vacuol
drug
could
act
simpli
increas
ph
fusion
could
occur
viral
infect
would
blockad
hypothesi
attract
import
observ
remain
contradict
present
thu
note
amantadin
resist
known
cor
relat
gene
code
protein
gene
code
ha
addit
problem
also
refer
virus
influenza
b
would
resist
amantadin
final
recent
studi
richman
et
al
show
amantadinetr
cell
wash
compound
free
medium
though
rel
high
concentr
amantadin
remain
intracellularli
cell
suscept
infect
yet
immedi
amantadin
cultur
medium
equilibr
cytoplasm
cell
resist
infect
impli
antivir
role
amantadin
superfici
extern
plasma
membran
cell
rather
intracellular
action
earlier
biolog
experi
amantadinetr
cell
show
incub
trypsin
remov
surfac
adher
materi
presum
amantadin
cell
becom
suscept
viral
infect
investig
ph
optimum
haemolysi
fig
number
b
virus
part
separ
studi
biolog
characterist
field
isol
influenza
viru
ph
optimum
fusion
shown
haemolysi
influenza
b
virus
drugresist
virus
higher
amantadin
sensit
influenza
virus
fusion
henc
infect
would
proceed
even
presenc
amantadin
ph
wherea
correspond
event
would
block
amantadinesensit
influenza
virus
although
small
reproduc
differ
ph
optimum
ph
maximum
haemolysi
note
amantadineresist
viru
maximum
ph
parent
amantadinesensit
viru
maximum
ph
nevertheless
close
rang
ph
shown
influenza
virus
tabl
addit
recombin
known
inherit
gene
gene
hlni
viru
thu
rel
resist
amantadin
like
parent
show
similar
ph
optimum
maximum
haemolysi
second
parent
strain
inhibit
amantadin
indulen
person
commun
approxim
pi
purifi
viru
mgml
adsorb
neutral
ph
ml
suspens
erythrocyt
ml
phosphatecitr
buffer
ad
ph
vari
unit
step
incub
h
lyse
cell
deposit
centrifug
optic
densiti
supernat
fluid
determin
use
unicam
sp
spectrophotomet
estim
degre
haemolysi
compar
rbc
incub
absenc
viru
ph
maximum
higher
ph
signific
haemolysi
occur
influenza
b
viru
show
high
ph
optimum
high
ph
maximum
haemolysi
similar
influenza
virus
ph
profil
although
neither
viru
inhibit
amantadin
tabl
final
anticip
high
concentr
ad
amantadin
inhibit
haemolysi
red
blood
cell
amantadinesensit
influenza
virus
thu
work
requir
investig
establish
role
fusion
event
determin
low
ph
haemolysi
red
blood
cell
caus
fusion
process
look
correl
ph
optimum
biolog
event
amantadin
resist
r
suscept
genet
phenotyp
heterogen
virus
may
consider
practic
import
attempt
control
certain
viru
diseas
chemoor
immunoprophylaxi
see
chapter
thu
certain
natur
circul
influenza
virus
may
resist
antivir
drug
amantadin
virtu
mutat
gene
may
differ
virul
antigen
biolog
properti
thu
may
abl
circumv
drug
induc
protect
studi
influenza
b
virus
circul
commun
shown
quit
extens
genet
phenotyp
variat
occur
thu
number
recent
isol
influenza
virus
h
antigen
subtyp
temperatur
sensit
phenotyp
differ
virul
volunt
chapter
laboratori
studi
artifici
induc
influenza
ts
mutant
demonstr
clearli
mutant
attenu
man
shutoff
temperatur
relat
attenu
occurr
nont
ts
virus
natur
probabl
indic
influenza
virus
vari
virul
circul
commun
studi
even
virus
isol
citi
vari
consider
phenotyp
ts
charact
influenza
b
virus
circul
commun
may
also
differ
respect
biolog
properti
plaqu
mdck
cell
electrophoret
properti
structur
nonstructur
polypeptid
rna
final
analysi
field
isol
influenza
b
virus
use
panel
monoclon
antibodi
viru
ha
indic
consider
degre
antigen
heterogen
even
among
virus
isol
rather
circumscrib
outbreak
singl
town
school
chapter
quit
possibl
biolog
techniqu
current
use
estim
degre
inhibit
virus
amantadin
insensit
signific
small
differ
drug
resist
virus
may
miss
differ
might
howev
signific
effect
circul
virus
commun
pharmacolog
amantadin
summari
establish
follow
oral
administr
amantadin
man
mice
concentr
amantadin
could
attain
tissu
would
expect
influenza
viru
inhibitori
effect
around
pg
amantadineg
tissu
howev
appear
clearli
establish
exact
intracellular
local
administ
amantadin
correl
antivir
activ
richman
et
al
follow
singl
oral
dose
amantadin
hydrochlorid
averag
dose
recov
urin
five
differ
subject
nine
occas
urin
collect
continu
day
averag
excret
hour
dose
base
determin
subject
tabl
maximum
blood
level
gener
reach
hour
oral
dose
tabl
evid
acetyl
methyl
form
amantadin
human
urin
sampl
examin
spite
effort
demonstr
presenc
extran
peak
observ
attribut
metabolit
drug
bleidner
et
al
aoki
et
al
investig
disposit
dose
nig
amantadin
taken
everi
h
day
healthi
young
adult
author
detect
rather
slower
absorpt
drug
compar
previou
studi
averag
time
peak
plasma
concentr
h
almost
complet
oral
bioavail
amantadin
indic
recoveri
approxim
gon
singl
oral
dose
median
ratio
plasma
renal
clearanc
amantadin
approxim
uniti
suggest
compound
extens
metabol
ize
distribut
amantadin
deriv
adamantan
human
volunt
given
singl
oral
dose
amantadin
level
amantadin
urin
determin
variou
time
thereaft
determin
subject
b
determin
subject
establish
postmortem
tissu
woman
parkinson
diseas
wesemann
et
al
patient
treat
x
mg
amantadin
molecul
daili
day
level
compound
pgg
tissu
follow
kidney
lung
spleen
blood
cerebellum
thu
particular
interest
rel
high
level
molecul
found
lung
level
amantadin
tissu
specimen
also
determin
girl
influenza
viru
pneumonia
fishaut
mostow
mgkg
amantadin
h
administ
tissu
specimen
obtain
h
final
dose
serum
concentr
rang
pgml
whilst
higher
concentr
amantadin
found
lung
pglml
level
compound
would
significantli
inhibit
replic
recent
h
n
influenza
virus
studi
pharmacolog
volunt
given
aerosol
amantadin
hayden
et
al
one
hour
aerosol
treatment
g
amantadin
per
ml
solut
glass
nebul
amantadin
level
nasal
wash
sampl
mean
pgjml
greatli
exceed
blood
nasal
wash
level
follow
oral
administr
littl
detail
work
publish
concern
pharmacolog
mani
deriv
amantadin
synthes
test
antivir
howev
vari
biolog
activ
molecul
would
suggest
differ
tissu
distribut
adsorpt
might
occur
exampl
rimantadin
induc
fewer
cn
side
effect
human
amantadin
might
relat
reduc
level
cn
sinc
exampl
compound
antiparkinson
diseas
activ
unlik
amantadin
activ
region
toxicolog
amantadin
central
nervou
stimul
effect
amantadin
describ
vernier
et
al
acut
chronic
toxic
studi
anim
concentr
around
mgkg
oral
time
dosag
man
predomin
sign
central
nervou
stimul
increas
motor
activ
tremor
anorexia
increas
sensit
environment
stimuli
convuls
case
stimul
effect
also
describ
volunt
given
high
dose
compound
rel
high
dose
anim
effect
transient
vasodepressor
effect
cardiac
arrhythmia
weak
ganglion
block
effect
increas
myocardi
contractil
forc
block
phenethylamin
vasopressor
respons
vernier
et
al
millet
et
al
carri
control
comparison
amantadin
rimantadin
cn
effect
includ
commonli
use
antihistamin
compound
chlorpheniramin
studi
carri
univers
california
adult
volunt
particip
mean
age
year
signific
differ
among
treatment
group
respect
age
sex
subject
mild
symptom
occur
approxim
equal
frequenc
group
therefor
exclud
analysi
tabl
show
frequenc
cumul
score
moder
sever
symptom
commonli
report
within
treatment
group
frequenc
report
symptom
low
amantadin
placebo
group
antihistaminelik
side
effect
drowsi
dri
mouth
less
frequent
sever
amantadin
group
chlorpheniramin
group
howev
moder
sever
inabl
concentr
dizzi
fatigu
report
frequent
subject
receiv
combin
amantadin
chlorpheniramin
two
subject
receiv
combin
report
addit
symptom
confus
distort
depth
percept
well
nausea
chill
signific
differ
group
mean
score
second
practic
trial
pretreat
trial
critic
track
test
among
treatment
group
tabl
effect
amantadin
rimantadin
higher
central
nervou
system
function
memori
attent
becom
import
consid
use
prophylaxi
larg
popul
data
millet
et
al
show
total
score
within
symptom
categori
treatment
group
repres
sum
total
daili
moder
sever
complaint
treatment
period
day
neither
drug
signific
effect
upon
perform
task
involv
attent
cognit
memori
earli
clinic
studi
rimantadin
ussr
smorodintsev
et
al
recent
usa
appar
indic
molecul
less
toxic
amantadin
dolin
et
al
fewer
cn
side
effect
note
although
effect
mild
amantadin
detect
patient
describ
abovese
tabl
recent
studi
hayden
et
al
found
similar
plasma
concentr
amantadin
rimantadin
differ
frequenc
sever
side
effect
oral
dose
volunt
concentr
mgday
amantadin
rimantadin
result
two
fold
differ
plasma
level
h
initi
dose
drug
ng
amantadin
ng
rimantadin
moreov
plasma
drug
concentr
correl
significantli
total
symptom
score
tabl
thu
import
conclus
amantadin
rimantadin
appear
differ
pharmacokinet
potenti
side
effect
compar
plasma
concentr
studi
kyo
et
al
amantadin
hydrochlorid
administ
oral
two
separ
dose
mgkg
higher
dose
group
mgkg
day
success
day
day
pregnanc
nullipara
rat
wistar
strain
age
month
order
examin
effect
upon
foetu
final
stage
pregnanc
postnat
growth
result
indic
slight
retard
increas
bodi
weight
dam
higher
dose
group
amantadin
effect
number
nidat
end
final
stage
pregnanc
higher
dose
group
howev
mortal
rate
foetu
drop
bodi
weight
surviv
litterm
show
signific
differ
control
group
although
malform
observ
group
final
observ
growth
litterm
end
postnat
week
spontan
parturit
group
indic
parturit
rate
significantli
lower
higher
amantadin
dose
group
control
group
amantadin
dose
test
effect
suckl
rate
extern
differenti
surviv
rate
auditori
sens
motil
develop
gonad
function
skelet
structur
contrast
studi
lamar
et
al
holtzman
rat
new
zealand
white
rabbit
dose
oral
amantadin
mgkg
day
prior
mate
day
pregnanc
rat
rabbit
result
autopsi
perform
day
gestat
show
signific
decreas
number
implant
increas
number
resorpt
mgkg
teratolog
studi
perform
rat
mgkg
administ
drug
oral
day
gestat
autopsi
expect
parturit
increas
resorpt
decreas
number
pup
per
litter
note
mgkg
gross
examin
rat
pup
dose
level
reveal
malform
mgkg
malform
mgkg
includ
oedema
malrot
hindlimb
miss
tail
stunt
brachygnatha
examin
clear
alizarinstain
skelet
prepar
foetus
reveal
case
absent
rib
absenc
lumbar
sacral
portion
spinal
column
mgkg
group
thu
rat
rabbit
amantadin
seem
embryotox
teratogen
teratogen
rat
occur
mgkgday
time
usual
human
dose
oxford
galbraith
contrast
control
trial
shown
neg
effect
cours
consider
interest
gener
agreement
literatur
protect
effect
amantadin
use
prophylact
influenza
viru
would
approxim
rang
place
figur
perspect
clinic
trial
influenza
vaccin
period
time
shown
similar
result
protect
effect
vari
loo
mean
approach
death
incid
moder
influenza
outbreak
approxim
wherea
incid
death
follow
vaccin
estim
million
lower
yield
maximum
benefit
risk
ratio
favour
immun
amantadin
vaccin
protect
efficaci
attack
rate
person
would
immun
given
amantadin
prevent
influenza
one
person
assum
mortal
rate
approxim
person
would
treat
immun
prevent
one
death
background
compar
interest
examin
repres
clinic
trial
carri
illustr
exactli
effect
amantadin
prevent
cure
influenza
infect
abl
assess
whether
compound
activ
enough
warrant
extens
use
futur
whether
amantadin
rimantadin
consid
first
antiinfluenza
compound
whether
new
compound
much
higher
degre
activ
would
requir
altern
expect
clinician
base
sever
decad
experi
antibacteri
high
realis
antivir
might
suitabl
mention
import
properti
antiinfluenza
compound
particularli
use
prophylact
would
complet
abort
influenza
viru
infect
rather
reduc
viru
replic
abort
clinic
sign
patient
would
thu
abl
produc
natur
immunolog
respons
confer
protect
reinfect
viru
immedi
drug
prophylaxi
ceas
follow
satisfactori
safeti
test
amantadin
anim
clearanc
food
drug
administr
usa
human
volunt
studi
begun
use
attenu
strain
influenza
viru
challeng
shall
consid
repres
artifici
natur
challeng
studi
amantadin
prophylact
therapeut
agent
attempt
analyz
data
clinic
trial
report
literaturerath
review
select
artifici
challeng
studi
advantag
method
involv
challeng
human
subject
known
viru
twofold
first
administr
conveni
result
clinic
investig
gener
immedi
compar
delay
involv
wait
natur
occur
outbreak
epidem
influenza
second
concern
use
viru
known
virul
host
sensit
chemoprophylact
agent
design
plan
meticul
detail
includ
screen
volunt
preexist
antibodi
challeng
viru
thu
possibl
involv
group
volunt
low
absent
antibodi
challeng
viru
compar
respons
seen
volunt
alreadi
possess
signific
level
antibodi
viru
time
challeng
possibl
object
method
investig
antiinfluenza
agent
may
dissimilar
infect
occur
natur
epidem
form
use
high
challeng
dose
viru
thu
present
vigor
test
bear
reed
initi
follow
discoveri
du
pont
compani
antivir
activ
amantadin
unit
state
clinic
studi
confin
america
howev
evid
prophylact
action
influenza
dissemin
clinic
investig
set
europ
far
east
gener
dosag
use
mg
everi
h
studi
notabl
smorodintsev
employ
mg
daili
clinic
studi
soviet
union
use
rimantadin
review
recent
kalninya
zlydnikov
et
al
therefor
discuss
detail
summar
tabl
initi
challeng
studi
jackson
et
al
select
volunt
amongst
colleg
student
submit
blood
specimen
determin
influenza
antibodi
titr
twothird
student
consid
high
serum
antibodi
titr
greater
subject
placebo
challeng
randomli
select
high
antibodi
group
subject
serv
placebo
control
observ
drug
toxic
among
initi
subject
low
antibodi
group
less
subject
challeng
influenza
viru
place
group
receiv
either
placebo
mg
amantadin
one
half
group
given
capsul
pretreat
begin
h
viru
challeng
half
receiv
treatment
begin
h
challeng
treatment
continu
next
day
challeng
ill
viru
recoveri
exfoli
cytolog
serolog
studi
among
volunt
challeng
influenza
viru
per
cent
fourfold
greater
rise
antibodi
convalesc
sera
indic
infect
challeng
viru
repres
infect
rate
per
cent
among
subject
prechalleng
antibodi
titr
lo
less
volunt
prechalleng
antibodi
titr
infect
rate
among
higher
serum
level
antibodi
becam
infect
among
two
placebo
group
b
subject
low
antibodi
titr
becam
infect
judg
serolog
rise
titr
among
higher
antibodi
infect
among
subject
pretreat
drug
consider
reduct
infect
observ
volunt
either
antibodi
statu
low
antibodi
subject
given
amantadin
infect
rate
statist
signific
reduct
p
compar
combin
group
therapeut
effect
detect
see
howev
earli
challeng
studi
carri
common
cold
research
centr
england
use
attenu
strain
influenza
sensit
amantadin
vitro
laboratori
studi
fail
demonstr
prophylact
action
drug
clinic
serolog
tyrrel
et
al
rel
larg
dose
eggadapt
viru
use
volunt
number
involv
small
togo
et
al
report
studi
perform
cooper
volunt
maryland
hous
correct
sixtyf
men
titr
less
neutral
antibodi
enrol
full
baselin
evalu
hous
research
ward
prison
oral
temperatur
puls
rate
respir
rate
record
fourhourli
interv
followup
specimen
collect
day
post
challeng
seven
trial
conduct
preliminari
potencytest
inoculum
seven
men
challeng
follow
six
drugevalu
studi
viral
challeng
perform
total
men
volunt
group
number
amantadin
lactosecontain
placebo
capsul
administ
doubleblind
techniqu
randomli
number
bottl
drug
given
mg
dose
twice
daili
eight
day
first
two
studi
nine
day
follow
four
studi
start
h
prior
viral
challeng
drugtreat
group
receiv
total
mg
amantadin
viru
dose
tcidso
given
nasopharyng
virul
viru
inoculum
examin
men
receiv
undilut
viru
fluid
contain
tcidso
clinic
ill
observ
classifi
accord
sever
sign
symptom
follow
criteria
appli
moder
ill
temperatur
c
occasion
respiratori
tract
sign
mild
ill
signific
symptomatolog
temperatur
c
question
ill
fever
compris
pertin
symptom
suspect
ill
subsequ
experi
volunt
enrol
drug
evalu
studi
show
similar
clinic
respons
induc
ill
gener
milder
natur
occur
influenza
prophylact
effect
amantadin
volunt
experiment
induc
influenza
infect
assess
six
separ
consecut
doubleblind
trial
sever
ill
occur
placebotr
subject
occurr
six
instanc
ill
placebotr
subject
compar
none
drugtreat
group
statist
signific
differ
pool
strike
dispar
overal
incid
clinic
ill
two
group
febril
ill
rate
observ
thirteen
patient
placebotr
group
compar
five
patient
febril
ill
amantadin
group
statist
signific
first
studi
amantadin
famili
environ
perform
galbraith
et
al
cooper
famili
doctor
major
member
epidem
observ
unit
royal
colleg
gener
practition
doctor
mani
experi
conduct
serolog
control
clinic
trial
ask
includ
studi
famili
five
index
case
five
contact
case
studi
famili
defin
occup
household
year
age
live
daili
contact
index
case
defin
first
person
age
year
contract
clinic
influenza
household
contact
case
defin
individu
live
household
contact
index
case
index
case
receiv
placebo
medic
order
influenc
possibl
spread
influenza
famili
index
contact
case
receiv
drug
placebo
random
alloc
member
one
famili
except
index
case
receiv
treatment
drug
placebo
diagnosi
influenza
index
case
made
clinic
epidemiolog
ground
doctor
first
visit
blood
taken
index
case
mani
member
famili
practic
second
blood
sampl
taken
two
three
week
later
test
hi
cf
antibodi
perform
daili
record
kept
bodi
temperatur
presenc
cough
cough
accompani
rise
temperatur
c
higher
taken
criterion
diagnosi
clinic
influenza
twentytwo
famili
doctor
studi
famili
compris
contact
divid
treat
placebo
group
index
case
per
cent
show
serolog
evid
influenza
infect
famili
serolog
evid
influenza
infect
index
case
two
contact
amantadinetr
group
develop
clinic
symptom
influenza
whilst
contact
correspond
placebo
group
develop
influenzalik
ill
differ
incid
two
group
margin
signific
p
howev
serolog
evid
infect
influenza
viru
two
individu
amantadin
group
develop
clinic
ill
contrast
placebo
group
ten
contact
pair
sera
avail
develop
antibodi
rise
influenza
tabl
serolog
confirm
case
influenza
consid
differ
drug
placebo
treat
group
significantli
differ
statist
author
also
observ
proport
contact
serolog
evid
influenza
infect
irrespect
clinic
ill
compar
placebo
drugtreat
group
tabl
differ
group
highli
signific
p
follow
winter
investig
repeat
famili
studi
face
epidem
new
pandem
viru
hong
kong
influenza
seventytwo
gener
practition
volunt
take
part
famili
includ
compris
individu
differ
design
studi
previou
year
index
case
famili
receiv
amantadin
placebo
keep
rest
famili
result
case
suffer
clinic
influenza
serolog
proof
influenza
infect
submit
statist
analysi
instanc
drug
placebotr
individu
behav
similarli
amantadin
fail
protect
person
receiv
compound
influenza
viru
equal
sensit
amantadin
previou
year
strain
author
sought
explain
revers
consid
initi
antibodi
statu
case
studi
seen
studi
initi
level
hi
antibodi
current
strain
influenza
higher
per
cent
initi
hi
antibodi
compar
studi
per
cent
contact
studi
possess
initi
hi
titr
may
respons
differ
administr
amantadin
half
number
index
case
could
influenc
infect
individu
direct
comparison
two
trial
possibl
studi
examin
prophylact
effect
amantadin
determin
effect
compound
spread
influenza
initi
index
case
left
untreat
rest
familv
usa
therapeut
effect
amantadin
man
clearli
establish
togo
et
al
studi
therapeut
effect
amantadin
amongst
patient
famili
environ
carri
gener
practition
unit
kingdom
report
galbraith
et
al
galbraith
et
al
fiftyseven
doctor
took
part
includ
patient
clinic
diagnos
influenza
amantadin
provid
capsul
form
mg
syrup
mg
ml
patient
receiv
activ
placebo
medic
random
number
alloc
doubleblind
basi
adult
receiv
mg
everi
h
children
age
year
mg
daili
younger
children
proport
dose
syrup
medic
start
time
patient
first
seen
doctor
continu
day
blood
sampl
taken
doctor
first
visit
second
week
later
test
hi
antibodi
viru
cf
antibodi
fourfold
greater
rise
either
test
taken
evid
influenza
infect
patient
enter
provid
result
satisfi
criteria
analysi
receiv
amantadin
placebo
mean
durat
fever
shown
tabl
differ
drug
placebotr
patient
significantli
differ
symptomatolog
exclud
fever
consid
differ
demonstr
two
group
may
due
lack
sensit
method
record
clinic
ill
recent
number
excel
doubl
blind
placebo
control
trial
carri
data
obtain
confirm
data
earlier
trial
virus
prophylact
trial
dolin
et
al
report
first
well
control
comparison
usa
prophylact
effect
rimantadin
amantadin
area
activ
influenza
surveil
doubleblind
placebo
control
trial
medic
amantadin
initi
within
hr
onset
symptom
continu
day
indic
earli
influenza
outbreak
commenc
caus
casesj
h
l
n
l
virus
case
total
volunt
enrol
mean
age
year
signific
differ
age
race
male
femal
ratio
level
preexist
hi
antibodi
throat
swab
viru
isol
taken
time
per
week
volunt
assign
amantadin
rimantadin
placebo
group
mg
tablet
taken
twice
daili
day
symptom
record
week
volunt
return
symptom
diari
coordin
centr
receiv
day
suppli
tablet
respiratori
ill
occur
volunt
ask
return
centr
rere
examin
physician
influenzalik
ill
defin
cough
andor
fever
greater
c
two
follow
symptom
sore
throat
headach
myalgia
trial
last
six
week
serum
sampl
obtain
begin
end
studi
serolog
analysi
significantli
placebo
recipi
develop
influenzalik
ill
compar
amantadin
rimantadin
group
give
reduct
rate
ill
respect
tabl
howev
note
previou
trial
review
oxford
galbraith
rate
laboratori
confirm
influenzalik
ill
reduc
rimantadin
amantadin
suggest
proport
influenza
like
ill
observ
studi
caus
influenza
viru
small
group
amantadin
patient
sampl
drug
detect
urin
ml
suggest
good
complianc
rate
total
volunt
left
studi
week
possibl
sideeffect
withdraw
ill
defin
cough
andor
fever
c
two
follow
sore
throat
headach
myalgia
rate
placebo
rimantadin
amantadin
excess
rate
latter
group
mainli
caus
cn
effect
includ
insomnia
jitteri
difficulti
concentr
although
symptom
gener
clear
within
hour
cessat
medic
amantadin
rimantadin
thu
highli
effect
prevent
ill
andor
infect
statist
signific
differ
efficaci
rate
two
compound
howev
amantadin
treat
person
significantli
cn
side
effect
excess
rate
compar
placebo
patient
author
conclud
rimantadin
might
compound
choic
chemoprophylaxi
influenza
infect
young
volunt
trial
could
carri
elderli
high
risk
individu
anoth
recent
clinic
trial
compar
therapeut
effect
amantadin
versu
rimantadin
h
l
n
l
viru
van
vori
et
al
trial
also
describ
detail
illustr
clinic
serolog
criteria
need
appli
comprehens
clinic
therapeut
studi
antiinfluenza
compound
studi
carri
group
univers
student
natur
infect
h
viru
clinic
criteria
use
initi
diagnosi
influenza
includ
presenc
headach
fever
malais
myalgia
less
hour
durat
accord
major
previous
report
therapeut
studi
benefit
note
person
enter
treatment
later
hour
initi
symptom
complet
histori
taken
admiss
trial
thereaft
clinic
examin
carri
hour
day
week
specif
sign
categor
grade
scale
oral
temperatur
measur
clinician
daili
nasal
wash
viru
isol
taken
time
admiss
studi
hour
acut
convalesc
sera
obtain
test
rise
titr
hi
antibodi
confirm
clinic
diagnosi
student
took
tablet
mg
morn
night
h
therapi
blood
taken
test
level
drugthi
import
factor
control
student
inde
take
medic
level
rang
pg
ml
whilst
viru
inhibit
pgml
drug
volunt
enter
studi
proven
infect
hini
viru
rather
high
rate
clinic
diagnosi
sinc
exampl
typic
gener
practition
trial
uk
normal
record
success
influenza
diagnosi
galbraith
et
al
total
symptom
score
calcul
three
group
arbitrari
level
clinic
improv
compar
pretreat
reach
amantadin
rimantadin
group
hour
reach
hour
placebo
group
p
improv
note
drug
treat
group
respiratori
system
sign
mean
temperatur
drug
treat
group
significantli
lower
p
placebo
group
interest
find
student
hour
commenc
studi
student
drug
treat
group
abl
attend
class
compar
placebo
group
although
initi
titr
excret
viru
similar
group
hour
proport
student
shed
viru
significantli
lower
group
treat
amantadin
rimantadin
student
develop
postinfect
hi
antibodi
infect
viru
minor
cn
side
effect
note
proport
student
amantadin
group
day
appear
less
import
relief
influenza
symptom
sinc
student
group
return
class
rapidli
student
placebo
group
author
conclud
therapeut
advantag
favour
amantadin
occur
hour
benefit
appear
justifi
therapeut
use
amantadin
rimantadin
especi
comparison
current
usag
non
specif
drug
antibiot
antihistamin
cough
suppress
summari
therefor
amantadin
rimantadin
clinic
trial
influenza
virus
result
protect
infect
clinic
diseas
prophylact
efficaci
would
approxim
influenza
vaccin
qualif
amantadin
effect
influenza
b
virus
compound
use
success
prevent
spread
viru
famili
hospit
factori
close
commun
prison
antivir
effect
consist
virus
differ
subtyp
hini
quit
clear
therapeut
effect
also
obtain
result
day
faster
recoveri
lower
temperatur
fewer
clinic
symptom
virus
perhap
significantli
point
view
viru
spread
commun
reduc
excret
viru
could
amantadin
use
success
wider
scale
present
health
author
countri
recommend
routin
use
influenza
vaccin
prevent
influenza
infect
person
design
special
risk
mortal
eg
older
person
diabet
asthmat
person
chronic
obstruct
heart
diseas
bronchiti
littl
attempt
made
provid
protect
commun
larg
abort
epidem
spite
well
document
econom
social
disrupt
mortal
caus
influenza
b
virus
review
stuartharri
schild
notabl
except
attempt
immun
popul
usa
aswin
viru
contain
vaccin
follow
outbreak
influenza
infect
fort
dix
camp
usa
necessarili
size
uncontrol
trial
live
attenu
influenza
vaccin
citi
ussr
china
could
argu
gener
prophylact
measur
could
institut
enthusiasm
vigour
present
measur
could
includ
prophylaxi
certain
group
amantadin
consensu
meet
usa
elliot
also
recent
meet
vienna
galasso
et
al
suggest
follow
group
consid
amantadin
prophylaxi
see
also
tabl
unvaccin
children
adult
high
risk
seriou
mortal
mortal
underli
diseas
includ
pulmonari
cardiovascular
metabol
neuromuscular
immunodefici
diseas
adult
whose
activ
vital
commun
function
vaccin
appropri
contemporari
influenza
vaccin
exampl
policemen
firemen
select
hospit
personnel
person
frequent
contact
other
may
influenza
consid
higher
risk
contract
influenza
gener
popul
person
semiclos
institut
environ
especi
older
person
receiv
current
influenza
vaccin
group
panel
conclud
benefittorisk
consider
less
clear
includ
elderli
patient
year
older
receiv
influenza
vaccin
addit
use
amantadin
hydrochlorid
prophylaxi
hospit
patient
presenc
demonstr
outbreak
take
consider
local
particular
risk
factor
condit
exampl
patient
galbraith
et
al
zlydnikov
et
al
nafta
et
al
finklea
et
al
smorodintsev
et
al
bloomfield
togo
et
al
hornick
et
al
jackson
et
al
smorodintsev
et
al
h
et
al
oker
blom
et
al
zlydnikov
et
al
nafta
et
al
likar
note
summari
countri
involv
trial
exhaust
earli
licens
usag
amantadin
subject
two
critic
review
sabin
howev
extens
field
use
two
compound
last
year
provid
data
answer
mani
earlier
question
unvaccin
adult
nevertheless
seriou
underli
diseas
place
potenti
high
mortal
group
follow
attack
influenza
eg
person
pulmonari
cardiac
mgtabol
immunolog
defici
amantadin
rimantadin
could
use
prophylact
person
vaccin
time
vaccin
adult
high
risk
attack
influenza
rimantadin
amantadinesuppl
protect
would
expect
rais
basic
protect
effect
vaccin
alon
singl
non
reactogen
dose
vaccin
new
pandem
viru
subtyp
would
expect
give
signific
protectiont
w
dose
vaccin
would
requir
particularli
subunit
split
viru
vaccin
therefor
amantadin
could
administ
prophylact
twothre
week
period
develop
vaccin
induc
immun
event
arriv
new
pandem
strain
influenza
viru
group
addit
individu
gener
commun
would
like
prophylaxi
exclud
would
young
children
pregnant
women
limit
amount
clinic
toxicolog
data
two
group
see
galasso
et
al
elliot
undergo
inhal
anaesthesia
may
higher
risk
seriou
complic
final
obviou
possibl
would
supplement
vaccin
induc
partial
protect
amantadin
partial
protect
studi
investig
possibl
addit
effect
vaccin
amantadin
approach
preliminari
result
encourag
review
zlydnikov
et
rais
protect
efficaci
vaccin
rimantadin
group
group
given
vaccin
rimantadin
infect
individu
rang
asymptomat
probabl
exist
least
ratio
clinic
subclin
case
mild
cold
symptom
typic
acut
influenza
extrem
case
viru
infect
lower
respiratori
tract
pneumonia
major
limit
amantadin
one
respect
narrow
spectrum
antivir
activ
limit
influenza
viru
margin
activ
limit
vitro
data
parainfluenza
virus
vsv
rubella
arenavirus
influenza
b
review
oxford
galbraith
hand
influenza
viru
epidem
year
clinic
diagnosi
rate
influenza
gener
practition
rel
high
shown
control
clinic
trial
uk
galbraith
et
al
appar
extend
use
amantadin
must
accompani
initi
clear
laboratori
virolog
data
establish
influenza
viru
spread
commun
clearli
recommend
vienna
report
uk
phl
royal
colleg
gener
practition
consider
experi
quickli
accur
estim
outbreak
influenza
viru
commun
similar
monitor
carri
usa
ussr
therefor
three
countri
particularli
prophylact
measur
could
initi
degre
virolog
certainti
ussr
exampl
commun
alreadi
encourag
use
rimantadin
prophylact
period
week
citi
outbreak
influenza
viru
rimantadin
purchas
pharmaci
without
prescript
approxim
three
week
cours
also
administ
free
charg
certain
organ
indulen
latvian
academi
scienc
person
commun
uk
usa
amantadin
prescrib
medic
practition
cost
day
cours
uk
approxim
parallel
situat
occur
certain
new
antiherp
compound
rapid
selfprescript
patient
first
sign
viru
induc
lesion
requir
show
benefici
clinic
effect
mention
briefli
certain
concept
establish
use
antibacteri
may
therefor
modifi
antivir
includ
relianc
patient
abil
initi
prophylaxi
must
expect
howev
widespread
usag
antivir
may
quickli
result
select
spread
drug
resist
variant
drug
resist
major
clinic
problem
antibacteri
time
encourag
search
effect
molecul
vienna
report
suggest
popul
group
amantadin
rimantadin
therapi
prophylaxi
use
rimantadin
base
conclus
recent
publish
data
establish
although
rimantadin
amantadin
similar
antivir
properti
rimantadin
mgday
demonstr
toxic
effect
therefor
choic
prophylaxi
hand
mild
side
effect
amantadin
less
exampl
mani
nonspecif
compound
use
present
treat
clinic
effect
influenza
notic
person
alreadi
suffer
clinic
effect
influenza
either
rimantadin
amantadin
use
therapi
ad
earli
studi
ussr
establish
use
rimantadin
summar
tabl
therapeut
effect
amantadin
aerosol
hayden
et
al
establish
aerosol
amantadin
young
adult
experienc
acut
ill
caus
influenza
viru
discern
modest
therapeut
antivir
effect
could
ad
aerosol
administr
use
rnore
recent
ribavirin
particular
respiratori
syncyti
viru
infect
adult
children
chapter
hayden
trial
effect
smallparticl
aerosol
therapi
amantadin
assess
random
doubleblind
studi
patient
natur
acquir
influenza
vir
day
us
infect
aerosol
treatment
min
either
distil
water
amantadin
hydrochlorid
ml
distil
water
given
three
time
day
four
day
amantadinetr
patient
experienc
significantli
rapid
resolut
clinic
sign
symptom
compar
placebotr
patient
resolut
fever
similar
group
aerosol
deliveri
amantadin
affect
frequenc
viral
isol
upper
respiratori
tract
secret
associ
trend
toward
reduc
quantiti
viral
shed
serial
pulmonari
function
test
found
import
differ
group
amantadinetr
patient
experienc
greater
frequenc
mild
local
side
effect
rhinorrhea
nasal
irrit
aerosol
exposur
aerosol
treatment
caus
appar
declin
pulmonari
function
summari
therefor
amantadin
group
molecul
long
gestat
two
decad
accumul
scientif
data
overwhelm
indic
clinic
use
compound
influenza
viru
infect
futur
studi
must
monitor
close
develop
drug
resist
strain
use
amantadin
lower
dosag
level
use
amantadin
rimantadin
prevent
mortal
special
risk
group
synthet
nucleosid
analogu
ribavirin
virazol
fig
shown
inhibit
multipl
dnaand
rnacontain
virus
includ
influenza
virus
sidwel
et
smith
kirkpatrick
tabl
influenza
type
b
viru
replic
inhibit
tissu
cultur
cell
ribavirin
compound
act
earli
stage
influenzainfect
cell
possibl
inhibit
product
essenti
nucleotid
henc
rna
synthesi
recent
aerosol
ribavirin
shown
clinic
effect
influenza
b
viru
infect
human
consid
detail
mcclung
et
al
inhibitori
effect
ribavirin
replic
number
differ
influenza
b
virus
measur
earli
studi
use
egg
piec
system
fazeka
de
st
groth
white
experi
ribavirin
ad
egg
piec
plate
final
concentr
mm
time
viru
infect
viru
titrat
ribavirin
treat
control
untreat
plate
plate
incub
day
oxford
nucleosid
analogu
mm
caus
signific
inhibit
log
id
jml
replic
rang
influenza
strain
human
equin
avian
swine
origin
includ
hswine
l
n
aport
chalmer
virus
addit
influenza
bhong
viru
inhibit
similar
degre
influenza
virus
multipl
fowl
plaqu
viru
afpvdutch
havlneql
cef
cell
also
inhibit
ribavirin
determin
plaqu
inhibit
test
effect
ribavirin
respiratori
viru
infect
mice
shown
tabl
kochhar
et
al
singl
ip
dose
ribavirin
rang
mgkg
dosag
excess
mgkg
teratogen
optim
teratogen
dose
vari
stage
develop
higher
advanc
stage
develop
depend
dose
stage
treatment
virtual
part
skeleton
includ
craniofaci
limb
bone
suscept
ribavirin
frequenc
multipl
skelet
defect
increas
dose
rais
stage
depend
defect
orofaci
bone
markedli
appar
treatment
day
result
shorten
maxilla
survivor
treatment
either
day
result
high
frequenc
reduct
length
upper
lower
jaw
treatment
day
result
low
incid
effect
maxilla
high
frequenc
reduct
deform
mandibl
ribavirin
vivo
vitro
inhibit
embryon
dna
synthesi
inhibit
transitori
seem
directli
relat
embryoleth
activ
drug
although
role
metabol
inhibit
group
mice
use
experi
treat
c
control
precipit
teratogenesi
clear
cytotox
action
ribavirin
prolifer
limb
bud
mesenchym
cell
directli
associ
origin
limb
deform
review
toxicolog
ribavirin
hillyard
summar
data
compound
earli
clinic
trial
ribavirin
influenza
gave
somewhat
conflict
result
tabl
investig
effect
ribavirin
natur
acquir
influenza
hini
viru
infect
young
adult
doubleblind
placebocontrol
trial
ribavirin
conduct
young
adult
male
natur
infect
influenza
viru
similar
hini
ribavirin
given
oral
dose
mgday
five
day
begin
within
h
onset
clinic
influenza
clinic
sign
symptom
influenza
quantit
viral
shed
ribavirinand
placebotr
group
ribavirin
treatment
associ
significantli
fewer
fourfold
greater
rise
antibodi
influenza
viral
antigen
complementfix
test
rise
haemagglutinationinhibit
antibodi
titr
occur
equal
frequenc
group
ribavirintr
group
experienc
signific
increas
bilirubin
reticulocyt
count
onset
therapi
suggest
ribavirin
treat
subject
decreas
synthesi
andor
increas
destruct
erythrocyt
treatment
effect
suffici
magnitud
suggest
haemolysi
involv
follow
successul
demonstr
antivir
efficaci
aerosolis
ribavirin
anim
model
versu
influenza
viru
also
volunt
knight
et
al
mcclung
et
al
recent
investig
antivir
efficaci
versu
influenza
b
viru
interest
approach
antivir
apart
ribavirin
shown
activ
anim
model
versu
influenza
b
viru
caus
mortal
seriou
morbid
year
see
student
come
health
centr
oral
temperatur
c
ill
less
h
durat
suggest
influenza
includ
studi
treatment
ribavirin
aerosol
commenc
within
hour
admiss
last
h
continu
follow
morn
regular
schedul
hour
treatment
pm
pin
initi
day
mcclung
et
al
entri
studi
sever
clinic
sign
similar
group
h
ill
ribavirin
treat
patient
improv
greater
extent
control
tabl
similarli
regard
temperatur
maximum
temperatur
lower
treat
patient
remain
lower
throughout
trial
period
tabl
first
hour
declin
viru
titr
nasal
wash
detect
treat
group
significantli
differ
control
group
next
day
conclus
rapid
recoveri
ribavirin
treat
patient
note
result
compar
obtain
previous
influenza
infect
knight
et
al
estim
dose
ribavirin
deposit
respiratori
tract
mgh
repres
first
report
success
treatment
influenza
b
infect
human
sinc
amantadin
exampl
effect
influenza
virus
amantadin
ribavirin
repres
class
compound
demonstr
effect
influenza
b
virus
clinic
compound
howev
weaknessess
amantadin
activ
influenza
virus
whilst
ribavirin
nucleosid
analogu
teratogen
immunosuppress
anim
potter
et
al
henc
may
insur
mountabl
problem
toxic
particularli
use
oral
prophylact
work
continu
find
effect
inhibitor
recent
tend
centr
around
inhibitor
specif
viru
enzym
influenza
rna
transcriptas
neuraminidas
synthet
competit
inhibitor
fusion
sequenc
influenza
ha
former
latter
approach
theoret
advantag
broad
specif
sinc
rna
polymeras
enzym
constitut
np
p
polypeptid
share
virtual
influenza
virus
wherea
fusion
sequenc
n
terminu
ha
molecul
also
share
ha
differ
subtyp
influenza
thought
like
inhibitor
develop
would
inhibit
influenza
virus
hope
influenza
b
virus
well
next
page
shall
attempt
summar
work
emphas
approach
could
exploit
near
futur
influenza
b
virus
rnadepend
rna
polymeras
activ
associ
core
chow
simpson
skehel
rnapolymeras
activ
detect
microsom
nuclei
influenzainfect
cell
virusassoci
enzym
transcrib
vitro
influenza
viru
genom
suggest
enzym
requir
viru
multipl
therefor
inhibitor
rna
polymeras
enzym
potenti
applic
chemoprophylact
agent
rnacontain
virus
helgstrand
oberg
see
also
chapter
ho
walter
describ
inhibit
cellassoci
rnadepend
rna
polymeras
influenza
h
n
viru
selenocystin
relat
compound
selenocystamin
dihydrochlorid
inhibit
virusassoci
rna
polymeras
enzym
number
influenza
b
virus
oxford
perrin
describ
vitro
inhibit
influenza
virusassoci
rnadepend
rna
polymeras
selenocystamin
dihydrochlorid
bathophenanthrolin
disodium
disulphon
certain
heterocycl
thiosemicarbazon
fig
properti
common
compound
abil
chelat
soft
heavi
metal
ion
zinc
copper
convers
similar
type
compound
possibl
chelat
diminish
show
significantli
eg
less
inhibitori
activ
influenza
viru
rnadepend
rna
polymeras
rna
polymeras
influenza
viru
metalloenzym
activ
select
chelat
agent
might
design
test
compound
test
present
also
inhibit
e
coli
rna
polymeras
zinc
metalloenzym
inhibitori
effect
mammalian
cell
polymeras
would
depend
configur
rna
polymeras
enzym
polypeptid
near
zinc
bind
site
also
rel
stabil
constant
zinc
polypeptid
ligand
compet
ligand
addit
problem
target
rna
polymeras
inhibitor
virusinfect
cell
attempt
made
use
liposom
sinc
certain
compound
describ
either
rel
insolubl
highli
charg
penetr
plasma
membran
cell
use
liposomeencapsul
chelat
agent
select
deliveri
chelat
agent
interior
cell
respiratori
tract
attract
possibl
perrin
liposom
fine
dispers
phospholipid
spherul
vesicl
around
pm
diamet
made
concentr
multipl
bilay
incorpor
water
lowmolecularweight
solut
compart
bimolecular
lamella
fig
liposom
taken
cell
pinocytosi
engulf
phagocyt
insid
cell
liposom
broken
lysosom
lipas
chelat
agent
drug
liber
liposom
may
protect
drug
metabol
modif
immunolog
reaction
lipid
composit
may
vari
consider
give
rang
membran
structur
charg
liposom
form
incorpor
base
stearylamin
anion
speci
diacetyl
phosphat
phosphatid
acid
use
encapsul
liposom
deposit
tissueretent
highli
charg
inhibitor
may
significantli
increas
model
experi
caedta
cadpta
use
effect
chelat
zinc
low
defin
toxic
experiment
anim
man
rational
experi
deplet
zinc
level
cell
upper
respiratori
tract
henc
prevent
format
inhibit
function
zinc
contain
influenza
rna
transcriptas
enzym
howev
preliminari
experi
influenza
virusinfect
ferret
mice
antivir
activ
detect
latter
compound
although
low
concentr
test
date
experi
select
activ
thiosemicarbazon
vivo
studi
mice
ferret
howev
abl
detect
viru
inhibitori
effect
effect
compound
mous
mortal
mean
day
death
clinic
sign
influenza
ferret
anim
given
mgkg
hour
experi
use
ahong
viru
includ
either
amantadin
ribavirin
control
compound
demonstr
inhibit
effect
particular
model
system
potter
et
al
describ
interest
relev
infant
rat
model
essenc
influenza
viru
replic
turbin
infant
rat
becom
suscept
challeng
huemopldu
influenza
initi
studi
carri
amantadin
polynucleotid
poli
first
studi
infant
rat
inocul
influenza
viru
later
given
h
influenza
develop
bacteraemia
develop
mening
contrast
virusinfect
rat
given
amantadin
concentr
mgkg
subcutan
interperiton
oral
rout
show
significantli
reduc
incid
bacteraemia
amantadin
treatment
intranas
rout
produc
signific
reduct
bacteri
infect
result
also
shown
parallel
studi
use
influenza
viru
second
similar
studi
use
influenza
viru
poli
also
reduc
incid
system
infect
tabl
sodium
evalu
antivir
activ
tissu
cultur
infect
mice
ohnishi
et
al
concentr
rang
ugml
drug
inhibit
cytopath
effect
mean
tissu
cultur
infect
dose
influenza
viru
awsn
afm
akumamoto
bgreat
lake
tabl
moreov
experi
perform
date
control
studi
volunt
confirm
activ
merigan
et
al
obvious
detail
studi
requir
influenza
respiratori
virus
interferon
would
expect
broad
spectrum
antivir
activ
vaccin
remain
present
main
way
prevent
epidem
influenza
b
virus
least
recent
vaccin
confin
group
special
risk
mortal
influenza
earlier
widespread
use
live
attenu
vaccin
ussr
declin
somewhat
countri
produc
enough
vaccin
immun
lo
popul
recent
vaccin
tend
inactiv
whole
viru
subunit
vaccin
review
selbi
whole
viru
vaccin
produc
past
decad
improv
technolog
ultracentrifug
gel
filtrat
rel
pure
viru
protein
ha
antigen
content
well
control
singl
radial
diffus
techniqu
wood
et
al
must
admit
mani
problem
remain
solv
discuss
detail
whilst
reader
also
refer
chapter
modern
approach
gene
clone
discuss
chapter
problem
antigen
genet
variat
outlin
see
also
tabl
laboratori
studi
establish
clearli
ha
na
antigen
contain
main
antigen
determin
viru
respons
induc
protect
immun
review
potter
oxford
passiv
antibodi
ha
na
protect
mice
lethal
infect
influenza
viru
well
immun
ha
na
antigen
lmmuniz
passiv
immun
antibodi
n
p
exampl
protect
effect
virelizi
et
al
fazeka
de
st
groth
graham
schild
et
al
geth
influenza
virus
murphi
et
al
russian
worker
administ
live
vaccin
oral
green
et
al
atassi
webster
although
cell
mediat
immun
see
chapter
well
et
al
may
aid
recoveri
influenza
nevertheless
import
correl
protect
efficaci
local
nasal
iga
serum
level
igg
neutral
antibodi
review
stuartharri
underpin
mountain
difficulti
major
one
origin
antigen
sin
franci
wherebi
observ
first
attack
influenza
leav
indel
immunolog
memori
ha
viru
subsequ
stimul
immun
system
infect
immun
often
lead
increas
synthesi
antibodi
ha
first
viru
rather
viru
actual
current
vaccin
difficult
imagin
approach
influenza
vaccin
could
overcom
difficulti
emphas
combin
approach
antivir
vaccin
may
repres
best
strategi
inactiv
influenza
b
viru
vaccin
prepar
nowaday
often
purif
recombin
kilbourn
schulman
pales
influenza
virion
harvest
infect
allanto
fluid
embryon
hen
egg
ratezon
centrifug
viru
approxim
pure
inactiv
formalin
ppropiolacton
standard
radial
immunodiffus
wood
et
al
rocket
immunoelectrophoresi
contain
around
pg
protein
per
human
vaccin
dose
use
high
growth
recombin
virus
kilbourn
contain
mani
gene
high
yield
laboratori
viru
h
gene
code
ha
na
wild
viru
approxim
dose
viru
vaccin
may
obtain
one
embryon
egg
quit
appar
applic
consider
technolog
time
span
requir
produc
enough
vaccin
immun
popul
million
person
usa
exampl
tabl
period
mani
week
must
necessarili
elaps
initi
outbreak
caus
new
influenza
viru
product
vaccin
antigen
variant
tabl
contrast
efficaci
exist
antivir
amantadin
establish
within
day
larg
scale
immun
tabl
attempt
usa
face
threaten
outbreak
viru
caus
anew
hlni
viru
genet
relat
caus
viru
pandem
remain
pig
popul
usa
sinc
pandem
human
howev
mass
vaccin
campaign
halt
hitherto
unrecogn
complic
vaccin
observ
guillainbarr
syndrom
progress
disord
central
nervou
system
keenlysid
et
nevertheless
campaign
consider
technolog
achiev
rapid
product
vaccin
quantiti
effici
administr
larg
scale
use
jet
gun
problem
inactiv
influenza
vaccin
relat
rather
low
efficaci
approxim
protect
poor
longev
immun
respons
year
evas
induc
immun
respons
antigen
mutant
viru
residu
toxic
vaccin
regard
latter
adult
person
receiv
current
inactiv
vaccin
notic
local
pain
sting
site
inocul
although
may
deter
futur
accept
vaccin
seriou
reaction
howev
children
unprim
adult
whole
viru
vaccin
popul
group
extend
use
inactiv
influenza
b
vaccin
could
recommend
may
induc
seriou
side
reaction
includ
fever
circumv
advers
effect
recent
develop
vaccin
subunit
prepar
contain
relev
antigen
induc
protect
immunitynam
two
surfac
glycoprotein
spike
viru
haemagglutinin
neuraminidas
review
tyrrel
smith
webster
laver
subunit
vaccin
less
reactogen
unfortun
also
less
immunogen
unprim
individu
studi
continu
attempt
improv
immun
respons
ha
subunit
exampl
addit
synthet
adjuv
muramyl
dipeptid
mdp
mdp
may
increas
b
cell
respons
ha
molecul
least
anim
model
excit
new
approach
incorpor
synthet
gene
transcrib
gene
code
ha
protein
revers
transcriptas
ecoi
plasmid
system
emtag
et
al
result
genet
engin
experi
bacterium
synthes
influenza
ha
amount
detect
immunoprecipit
around
pgml
see
also
chapter
experi
geth
sambrook
howev
stage
mani
obstacl
remain
firstli
ha
constitut
total
protein
synthes
bacterium
transport
exterior
thu
ha
releas
lyse
bacteria
purifi
ecoi
protein
endotoxin
although
ha
clearli
possess
antigen
determin
prime
import
vaccin
retent
immunogen
probabl
enzymat
degrad
occur
presenc
ecoi
proteas
thu
ha
molecul
may
monom
form
similar
ha
remov
viru
proteolyt
enzym
bromelain
case
molecul
may
poorli
immunogen
may
need
reconstitut
onto
virosom
exampl
increas
immun
respons
hand
technolog
bacteri
cultiv
larg
scale
well
advanc
singl
larg
ferment
batch
could
produc
theoret
mg
ha
enough
antigen
dose
vaccin
current
formul
note
ntermin
region
fusion
region
believ
involv
initi
infect
uncoat
influenza
viru
xray
structur
first
residu
region
appear
access
antibodi
least
low
ph
involv
viral
infect
antibodi
may
aris
region
cours
defenc
viral
infect
eleg
studi
atassi
webster
synthet
peptid
compris
region
residu
influenza
viru
influenza
b
viru
carri
investig
antigen
region
ha
molecul
two
peptid
compris
fusion
region
residu
part
ha
strain
strain
b
influenza
viru
synthes
abil
bind
rabbit
goat
human
antiinfluenza
antibodi
determin
quantit
immunoadsorb
titrat
two
peptid
bound
consider
amount
antibodi
rabbit
goat
antisera
viru
ha
b
strain
well
sever
human
sera
patient
recov
influenza
antiha
monoclon
antibodi
bound
complet
bound
partial
peptid
antibodi
rais
rabbit
peptid
immun
peptidebovin
serum
albumin
conjug
free
peptid
antipeptid
antibodi
rere
bound
ha
intact
viru
respect
strain
howev
antisera
fail
exhibit
signific
viru
neutral
activ
find
sera
sever
individu
viral
infect
larg
amount
antibodi
direct
fusion
region
unequivoc
establish
import
antigen
site
viru
ha
human
condit
natur
influenza
infect
comparison
rel
strong
immunogen
activ
locat
weak
antigen
report
region
residu
carbohydr
side
chain
hai
recent
peptid
compris
almost
ha
molecul
synthes
green
et
al
even
though
antigen
coupl
protein
carrier
none
peptid
react
antiha
antibodi
indic
contain
antigen
site
ha
antigen
site
describ
atassi
webster
one
four
antigen
region
suggest
examin
xray
structur
ha
see
howev
access
involv
infect
also
site
predict
empir
approach
basi
hydrophil
index
fact
fusion
region
hydrophob
synthet
peptid
insolubl
aqueou
solvent
antigen
site
expect
resid
access
surfac
region
everi
surfac
region
constitut
antigen
site
thu
exposur
suffici
criterion
immunogen
furthermor
antigen
site
necessarili
highli
hydrophil
region
hydrophob
interact
frequent
provid
major
contribut
bind
energi
also
seen
report
haemoglobin
achain
major
antigen
site
could
resid
surfac
region
low
hydrophiliciri
mostli
hydrophob
region
render
access
threedimension
oligomer
characterist
particular
protein
summari
studi
excel
start
mani
potenti
peptid
remain
investig
also
possibl
antibodi
induc
although
convent
neutral
activ
may
still
inhibit
viru
releas
infect
biolog
system
sinc
shall
examin
data
detail
c
u
live
viru
approach
see
interest
examin
problem
convent
inactiv
influenza
vaccin
excel
studi
post
offic
uk
data
accru
answer
question
vaccin
efficaci
safeti
accept
healthi
person
work
industri
firstli
data
tabl
emphas
import
influenza
caus
sick
absenc
group
worker
tabl
show
data
subject
reaction
employe
follow
inactiv
live
influenza
vaccin
vaccine
experienc
local
even
gener
reaction
vaccin
perhap
reflect
accept
rate
vaccin
success
year
declin
tabl
particular
interest
observ
year
period
day
lost
sick
absenc
fewer
vaccin
group
compar
unvaccin
group
although
fluctuat
note
year
year
certif
sick
absenc
also
reduc
significantli
influenza
noninfluenza
period
tabl
show
placebo
effect
medic
attent
person
report
ill
might
ad
recent
analysi
econom
save
vaccin
old
person
usa
shown
consider
econom
benefit
riddiough
et
al
altern
approach
use
live
attenu
influenza
vaccin
bear
et
al
richman
murphi
theori
greater
opportun
rapid
product
sinc
dose
live
viru
vaccin
recov
singl
embryon
hen
egg
altern
influenza
viru
strain
cultiv
human
diploid
cell
may
also
theoret
advantag
herrero
et
al
schild
et
al
also
experiment
evid
immun
result
administr
live
attenu
vaccin
broader
induc
inactiv
vaccin
may
help
circumv
perenni
problem
antigen
drift
review
potter
oxford
earli
studi
two
group
virologist
one
leningrad
alexandrova
smorodintsev
one
ann
arbor
maassab
adapt
influenza
virus
low
temperatur
cold
adapt
mutant
ca
mutant
investig
potenti
virus
attenu
viru
strain
virus
replic
c
henc
least
theori
would
replic
lower
respiratori
tract
would
expect
view
accumul
mutat
show
sign
attenu
laboratori
recombin
virus
reassort
genom
l
u
mutant
recent
virul
antigen
variant
made
assess
virul
volunt
way
recombin
select
ca
gene
one
parent
ha
na
gene
virul
parent
recombin
virus
appar
attenu
man
altern
much
investig
possibl
induc
temperatur
sensit
lesion
lesion
well
character
donor
strain
influenza
viru
master
mistress
strain
transfer
gene
respons
ts
defect
togeth
gene
code
ha
na
current
virul
viru
make
laboratori
recombin
murphi
et
al
rational
similar
ca
approachvirus
unabl
replic
c
infect
cell
lower
respiratori
tract
man
henc
would
expect
show
reduc
virul
properti
howev
complic
earlier
studi
fs
mutant
tendenc
revert
back
virul
non
phenotyp
less
problem
cci
mutant
present
look
hope
futur
studi
third
gener
approach
live
attenu
influenza
vaccin
virus
recombin
prepar
old
attenu
laboratori
viru
h
l
n
probabl
host
rang
mutant
sinc
adapt
ferret
mice
egg
thu
deadapt
human
recent
virul
viru
virus
ha
na
gene
virul
viru
parent
remain
gene
attenu
parent
investig
volunt
attenu
bear
et
al
shown
quit
clearli
howev
occasion
recombin
still
retain
virul
man
oxford
et
al
studi
therefor
proceed
caution
present
complex
epidemiolog
situat
influenza
viru
two
antigen
subtyp
cocircul
h
n
introduc
complic
live
vaccin
two
laboratori
attenu
recombin
administ
man
addit
recombin
event
may
occur
naturo
lead
new
virus
perhap
virul
properti
howev
process
probabl
occur
anyway
natur
pales
young
two
live
vaccin
virus
administ
togeth
may
interfer
replic
potter
et
al
result
develop
distort
immun
respons
singl
viru
thu
mani
problem
remain
solv
influenza
vaccin
develop
use
specif
antiinfluenza
viru
inhibitor
popul
group
extend
use
vaccin
could
recommend
similar
suggest
antivir
tabl
excel
summari
ca
viru
studi
carri
mainli
usa
ussr
publish
kendal
et
al
shall
content
reexamin
summar
data
typic
biolog
characterist
cu
master
mistress
virus
outlin
tabl
whilst
method
obtain
ca
ann
arbor
strain
passag
laboratori
c
illustr
tabl
candid
vaccin
strain
test
exhaust
anim
model
replic
well
cooler
part
upper
respiratori
tract
ferret
mous
lower
respiratori
tract
protocol
phase
test
volunt
outlin
tabl
appar
candid
viru
test
immunogen
side
reaction
tabl
replic
temperatur
marker
coldadapt
virus
use
parent
prepar
recombin
vaccin
candid
kendal
et
al
replic
coldadapt
parent
viru
egg
c
kendal
et
al
gener
procedur
preble
potenti
vaccin
particip
test
prestudi
serum
hi
neutral
enzymelink
immunosorb
elisa
assay
identifi
volunt
maximum
suscept
vaccin
viru
quarantin
select
volunt
restrict
access
area
day
monitor
develop
ill
blind
condit
administ
drop
vaccin
placebo
mlnostril
supin
volunt
approxim
particip
receiv
vaccin
remaind
placebo
monitor
febril
system
respiratori
reaction
collect
daili
nasal
wash
specimen
week
collect
final
serum
specimen
volunt
depart
restrict
access
area
b
laboratori
test
specimen
collect
inocul
tube
cultur
monkey
kidney
mk
madindarbi
canin
kidney
mdck
cell
permiss
temperatur
dilut
nasal
wash
specimen
titrat
postinocul
replic
viru
verifi
cessat
viru
shed
addit
viru
isol
studi
undertaken
diagnos
possibl
noninfluenza
infect
case
ill
particip
inocul
tube
cultur
mk
mdck
cell
nonpermiss
temperatur
low
dilut
nasal
wash
specimen
detect
possibl
revert
nont
viru
titrat
viru
isol
primari
chicken
kidney
cell
examin
stabil
ca
ts
marker
titrat
preand
postinocul
sera
specimen
hi
case
neutral
elisa
procedur
detect
quantit
humor
antibodi
respons
case
titrat
nasal
wash
specimen
neutral
elisa
procedur
quantit
local
antibodi
respons
small
group
volunt
quarantin
condit
sampl
collect
volunt
examin
biolog
marker
includ
import
cu
properti
problem
ts
virus
test
doubli
seroneg
children
antibodi
either
ha
na
non
ts
revert
virus
tend
appear
slow
programm
develop
ts
influenza
virus
usa
typic
result
immunogen
publish
trial
ann
arbor
leningrad
vaccin
virus
given
tabl
virus
shown
induc
antibodi
volunt
whilst
produc
seriou
side
reaction
importantli
subsequ
challeng
immun
volunt
show
protect
clinic
sign
influenza
infect
therefor
studi
progress
ca
mutant
reason
safeti
progress
slowli
one
could
ask
exampl
whether
recombin
natur
ca
wild
viru
could
lead
virul
recombin
would
ca
virus
show
clinic
effect
chronic
bronchit
person
preexist
respiratori
diseas
final
allud
chapter
genet
engin
biochem
methodolog
could
lead
new
vaccin
candid
lesion
insert
specif
point
genom
